Drug Safety Update - January 2022
The Medicines and Healthcare products Regulatory Agency (MHRA) has published Drug Safety Update for January 2022 (PDF).
This issue contains the latest COVID-19 vaccine and medicine information including information on the approval of Paxlovid® for the treatment of COVID-19 in adults who are at risk of developing severe illness. It is noted that this medication may interact with other medications. Before it is prescribed, the MHRA is therefore advising that patients’ current medications should be carefully reviewed. Further information is available in the Summary of Product Characteristics.
Lastly in this issue is a summary of letters to healthcare professionals in December. These generally related to supply issues and recalls.
Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.
| « SMC Update - January 2022 | NICE Guidance - January 2022 » |
Leave a Comment